

Electronic Supplementary Information

Highly emissive planarized *B,N*-diarylated benzonaphthoazaborine compounds for narrowband blue fluorescence


Ngoc Tuyet Nhi Nguyen,[†] Hanif Mubarak,[†] Taehwan Lee, Thi Quyen Tran, Jaehoon Jung* and Min Hyung Lee*

Department of Chemistry, University of Ulsan, Ulsan 44610, Republic of Korea

General considerations

All operations were performed under an inert nitrogen atmosphere using standard Schlenk and glovebox techniques. Anhydrous grade solvents were used after drying over activated molecular sieves (5Å). Spectrophotometric-grade toluene was used for photophysical measurements. Commercial reagents were used without further purification after purchase. Deuterated solvents from Eurisotop were used. NMR spectra were recorded on a Bruker AM 300 (300.13 MHz for ^1H , 75.47 MHz for ^{13}C) or a Bruker AVANCE III HD 400 (128.38 MHz for ^{11}B) spectrometer at ambient temperature. Chemical shifts (in ppm) are referenced against external Me_4Si (^1H , ^{13}C) and $\text{BF}_3\cdot\text{OEt}_2$ (^{11}B). Mass spectra were obtained using a JEOL JMS700 high-resolution EI-mass spectrometer (HR EI-MS) at the Korea Basic Science Institute (KBSI), Daegu, Korea. Cyclic voltammetry experiments were carried out on a CHI600E system. The photophysical analysis was done by using an FS5 spectrophotometer (Edinburgh Instruments) and PLQY spectrophotometer (Quantaaurus-QY C11347-11, Hamamatsu Photonics) at total-period analysis center for Ulsan chemical industry of KBSI.

Synthesis



1a, R¹ = H

4a, R¹ = Me

5a, R¹ = ^tBu

3-Bromo-*N*-(2-bromophenyl)naphthalen-2-amine (**1a**)

The mixture of 2,3-dibromonaphthalene (3.00 g, 10.50 mmol), 2-bromoaniline (1.20 g, 7.00 mmol), tris-(dibenzylideneacetone)dipalladium(0) ($\text{Pd}_2(\text{dba})_3$, 0.19 g, 0.21 mmol), bis[(2-diphenylphosphino)phenyl] ether (DPEPhos, 0.23 g, 0.42 mmol), and sodium *tert*-butoxide (NaO^tBu , 1.00 g, 10.5 mmol) in dry toluene (30 mL) was heated at 80 °C for 12 h. After cooling down, the mixture was diluted with CH_2Cl_2 (30 mL), filtered through celite pad, and concentrated under reduced pressure. The crude product was subjected to silica gel column chromatography using CH_2Cl_2 /hexane (1:10, v/v) as an eluent to give **1a** as a white solid (yield: 1.40 g, 53%). ^1H NMR (CDCl_3): δ 8.13 (s, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.64–7.60 (m, 3H), 7.45 (ddd, J = 13.8, 8.2, 6.8 Hz, 2H), 7.36 (dd, J = 8.1, 1.2 Hz, 1H), 7.30 (dd, J =


7.3, 1.4 Hz, 1H), 6.92–6.86 (m, 1H), 6.62 (br, 1H). ¹³C NMR (CDCl₃): δ 140.1, 137.5, 133.4, 133.4, 132.2, 129.9, 128.3, 127.0, 126.8, 126.6, 124.7, 122.9, 118.6, 115.6, 114.7, 112.7.

3-Bromo-*N*-(2-bromo-5-methylphenyl)naphthalen-2-amine (4a)

This compound was prepared in a manner analogous to the synthesis of **1a** using Pd₂(dba)₃ (0.23 g, 0.25 mmol), DPEPhos (0.27 g, 0.5 mmol), NaO^tBu (1.21 g, 12.58 mmol), 2,3-dibromonaphthalene (2.4 g, 8.39 mmol), and 2-bromo-5-methylaniline (1.04 g, 5.59 mmol) to give **4a** as a white powder (yield: 1.10 g, 51%). ¹H NMR (CDCl₃): δ 8.13 (s, 1H), 7.69 (d, *J* = 8.0 Hz, 1H), 7.64 (d, *J* = 8.1 Hz, 1H), 7.60 (s, 1H), 7.49 (d, *J* = 8.1 Hz, 1H), 7.46–7.40 (m, 1H), 7.35 (m, 1H), 7.28 (d, *J* = 1.7 Hz, 1H), 6.72 (dd, *J* = 8.2, 1.9 Hz, 1H), 6.54 (br, 1H), 2.30 (s, 3H). ¹³C NMR (CDCl₃): δ 139.8, 138.5, 137.7, 133.4, 133.0, 132.2, 129.9, 126.9, 126.8, 126.6, 124.6, 124.1, 119.4, 115.6, 112.8, 111.6, 21.5.

3-Bromo-*N*-(2-bromo-5-(*tert*-butyl)phenyl)naphthalen-2-amine (5a)

This compound was prepared in a manner analogous to the synthesis of **1a** using Pd₂(dba)₃ (0.09 g, 0.10 mmol), DPEPhos (0.11 g, 0.21 mmol), NaO^tBu (0.50 g, 5.25 mmol), 2,3-dibromonaphthalene (2.0 g, 7.0 mmol), and 2-bromo-5-(*tert*-butyl)aniline (0.79 g, 3.50 mmol) to give **5a** as a white powder (yield: 1.20 g, 79%). ¹H NMR (CDCl₃): δ 8.13 (s, 1H), 7.68 (d, *J* = 8.1 Hz, 1H), 7.61–7.52 (m, 4H), 7.42 (ddd, *J* = 8.2, 6.9, 1.3 Hz, 1H), 7.33 (ddd, *J* = 8.0, 6.9, 1.2 Hz, 1H), 6.95 (dd, *J* = 8.4, 2.3 Hz, 1H), 6.60 (s, 1H), 1.31 (s, 9H). ¹³C NMR (CDCl₃): δ 151.8, 139.2, 138.0, 133.4, 132.8, 132.2, 129.6, 127.0, 126.8, 126.5, 124.4, 120.7, 117.1, 115.2, 112.1, 111.3, 34.9, 31.3.



1b, R¹ = R² = H

3b, R¹ = H, R² = ^tBu

4b, R¹ = Me, R² = ^tBu

5b, R¹ = ^tBu, R² = ^tBu

3-Bromo-*N*-(2-bromophenyl)-*N*-phenylnaphthalen-2-amine (1b)

The mixture of **1a** (1.40 g, 3.71 mmol), iodobenzene (3.80 g, 18.60 mmol), copper iodide (0.35 g, 1.86 mmol), and potassium carbonate (1.50 g, 11.13 mmol) was refluxed at 200 °C for 24 h. After cooling to room temperature, CH₂Cl₂ (30 mL) and water (50 mL) were added to the mixture. The organic layer

was separated and the aqueous layer was extracted with CH₂Cl₂ three times (30 mL × 3). The combined organic layer was washed with brine, dried over MgSO₄, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography using CH₂Cl₂/hexane (1:10, v/v) as an eluent to give **1b** as a white solid (yield: 1.45 g, 86%). ¹H NMR (CDCl₃): δ 8.16 (s, 1H), 7.77–7.71 (m, 1H), 7.64 (d, *J* = 7.0 Hz, 2H), 7.52 (s, 1H), 7.45 (dd, *J* = 6.0, 3.2 Hz, 2H), 7.23 (dt, *J* = 19.4, 7.3 Hz, 4H), 7.07 (t, *J* = 7.5 Hz, 1H), 7.00 (t, *J* = 7.2 Hz, 1H), 6.78 (d, *J* = 7.9 Hz, 2H). ¹³C NMR (CDCl₃): δ 147.8, 146.2, 143.2, 134.8, 133.6, 133.2, 132.2, 129.5, 129.1, 128.5, 127.4, 127.1, 126.8, 126.7, 126.5, 126.4, 122.2, 122.0, 121.4, 121.3.

3-Bromo-*N*-(2-bromophenyl)-*N*-(4-(*tert*-butyl)phenyl)naphthalen-2-amine (3b)

This compound was prepared in a manner analogous to the synthesis of **1b** using **1a** (2.0 g, 5.3 mmol), copper iodide (0.50 g, 2.65 mmol), potassium carbonate (2.19 g, 15.90 mmol), and 1-(*tert*-butyl)-4-iodobenzene (6.9 g, 26.52 mmol) to give **3b** as a white powder (yield: 1.90 g, 72%). ¹H NMR (CDCl₃): δ 8.13 (s, 1H), 7.73 (dd, *J* = 6.0, 3.2 Hz, 1H), 7.64–7.59 (m, 2H), 7.46–7.40 (m, 3H), 7.22 (d, *J* = 8.5 Hz, 3H), 7.14 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.07–7.01 (m, 1H), 6.71 (d, *J* = 8.7 Hz, 2H), 1.30 (s, 12H). ¹³C NMR (CDCl₃): δ 146.6, 145.3, 145.1, 143.6, 134.7, 133.5, 133.2, 132.0, 129.2, 128.4, 127.3, 126.8, 126.6, 126.2, 126.1, 125.9, 122.0, 122.0, 121.5, 121.4, 34.4, 31.6.


3-Bromo-*N*-(2-bromo-5-methylphenyl)-*N*-(4-(*tert*-butyl)phenyl)naphthalen-2-amine (4b)

This compound was prepared in a manner analogous to the synthesis of **1b** using **4a** (1.1 g, 2.81 mmol), copper iodide (0.26 g, 1.40 mmol), potassium carbonate (1.16 g, 8.43 mmol), and 1-(*tert*-butyl)-4-iodobenzene (3.65 g, 14.06 mmol) to give **4b** as a white powder (yield: 0.90 g, 61%). ¹H NMR (CDCl₃): δ 8.13 (s, 1H), 7.73 (dd, *J* = 6.2, 3.2 Hz, 1H), 7.63 (dd, *J* = 6.0, 3.4 Hz, 1H), 7.49–7.40 (m, 4H), 7.22 (d, *J* = 8.7 Hz, 2H), 6.94 (s, 1H), 6.86 (d, *J* = 8.1 Hz, 1H), 6.68 (d, *J* = 8.7 Hz, 2H), 2.23 (s, 3H), 1.30 (s, 9H). ¹³C NMR (CDCl₃): δ 146.0, 145.3, 144.8, 143.6, 138.5, 134.3, 133.5, 133.2, 132.0, 129.8, 127.3, 127.3, 126.8, 126.7, 126.6, 126.1, 125.9, 121.6, 121.1, 118.7, 34.3, 31.6, 21.1.

3-Bromo-*N*-(2-bromo-5-(*tert*-butyl)phenyl)-*N*-(4-(*tert*-butyl)phenyl)naphthalen-2-amine (5b)

This compound was prepared in a manner analogous to the synthesis of **1b** using **5a** (1.2 g, 2.77 mmol), copper iodide (0.26 g, 1.38 mmol), potassium carbonate (1.15 g, 8.31 mmol), and 1-(*tert*-butyl)-4-iodobenzene (3.60 g, 13.85 mmol) to give **5b** as a white powder (yield: 1.20 g, 75%). ¹H NMR (CDCl₃): δ 8.14 (s, 1H), 7.73 (dd, *J* = 5.8, 3.1 Hz, 1H), 7.64 (dd, *J* = 6.1, 3.1 Hz, 1H), 7.55–7.49 (m, 2H), 7.43 (dd, *J* = 5.8, 2.7 Hz, 2H), 7.21 (d, *J* = 9.2 Hz, 3H), 7.07 (d, *J* = 8.4 Hz, 1H), 6.66 (d, *J* = 8.2 Hz, 2H),

1.30 (s, 9H), 1.20 (s, 9H). ^{13}C NMR (CDCl_3): δ 152.0, 145.8, 145.2, 144.5, 143.4, 134.0, 133.5, 133.2, 132.0, 127.4, 126.8, 126.8, 126.7, 126.5, 126.1, 125.8, 123.6, 121.6, 120.6, 118.8, 34.7, 34.3, 31.6, 31.3.



1c, $\text{R}^1 = \text{R}^2 = \text{H}$

3c, $\text{R}^1 = \text{H}$, $\text{R}^2 = \text{tBu}$

4c, $\text{R}^1 = \text{Me}$, $\text{R}^2 = \text{tBu}$

5c, $\text{R}^1 = \text{R}^2 = \text{tBu}$

12,12-Dimethyl-5-phenyl-5,12-dihydrobenzo[b]naphtho[2,3-e][1,4]azasiline (**1c**)

To a solution of **1b** (1.50 g, 3.31 mmol) in dry THF (30 mL) was added dropwise *n*-BuLi (2.5 M in hexane, 2.65 mL, 6.62 mmol) at -78 °C. The mixture was stirred at -78 °C for 1 h and then Me_2SiCl_2 (0.43 g, 3.31 mmol) was slowly added. After stirring at room temperature overnight, the resulting white turbid mixture was quenched by saturated aqueous NH_4Cl solution (50 mL) and extracted with diethyl ether (30 mL \times 3). The combined organic layer was dried over MgSO_4 , filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography using CH_2Cl_2 /hexane (1:10, v/v) as an eluent to give **1c** as a white powder (yield: 0.97 g, 83%). ^1H NMR (CDCl_3): δ 8.10 (s, 1H), 7.78 (d, $J = 7.8$ Hz, 1H), 7.70 (dd, $J = 10.3, 4.7$ Hz, 2H), 7.63–7.54 (m, 2H), 7.43 (d, $J = 8.0$ Hz, 1H), 7.39–7.35 (m, 2H), 7.33–7.24 (m, 2H), 7.16 (ddd, $J = 8.8, 7.2, 1.8$ Hz, 1H), 6.99 (dt, $J = 7.1, 3.6$ Hz, 1H), 6.62 (s, 1H), 6.38 (d, $J = 8.6$ Hz, 1H), 0.62 (s, 6H). ^{13}C NMR (CDCl_3): δ 149.8, 146.9, 144.0, 135.3, 134.8, 134.4, 131.3, 131.2, 130.2, 128.1, 128.0, 127.3, 127.2, 126.7, 123.5, 122.8, 119.8, 119.0, 117.2, 112.1, 0.4.

5-(4-(*Tert*-butyl)phenyl)-12,12-dimethyl-5,12-dihydrobenzo[b]naphtho[2,3-e][1,4]azasiline (**3c**)


This compound was prepared in a manner analogous to the synthesis of **1c** using **3b** (1.94 g, 3.82 mmol) to give **3c** as a white powder (yield: 1.14 g, 73%). ^1H NMR (CDCl_3): δ 8.08 (s, 1H), 7.76 (dd, $J = 8.0, 1.3$ Hz, 1H), 7.69–7.65 (m, 2H), 7.59 (dd, $J = 7.1, 1.8$ Hz, 1H), 7.44 (d, $J = 8.0$ Hz, 1H), 7.33–7.22 (m, 4H), 7.16 (ddd, $J = 8.9, 7.2, 1.9$ Hz, 1H), 6.96 (t, $J = 6.9$ Hz, 1H), 6.62 (s, 1H), 6.38 (d, $J = 8.4$ Hz, 1H), 1.47 (s, 9H), 0.60 (s, 6H). ^{13}C NMR (CDCl_3): δ 151.1, 150.0, 147.1, 141.2, 135.2, 134.8, 134.3, 130.6, 130.2, 128.1, 128.0, 127.3, 127.2, 126.6, 123.4, 122.7, 119.6, 118.8, 117.1, 112.0, 35.0, 31.7, 0.5.

5-(4-(*Tert*-butyl)phenyl)-3,12,12-trimethyl-5,12-dihydrobenzo[*b*]naphtho[2,3-*e*][1,4]azasiline (4c)

This compound was prepared in a manner analogous to the synthesis of **1c** using **4b** (0.90 g, 1.72 mmol) to give **4c** as a white powder (yield: 0.54 g, 75%). ¹H NMR (CDCl₃): δ 8.05 (s, 1H), 7.75 (d, *J* = 7.9 Hz, 1H), 7.68–7.63 (m, 2H), 7.48 (d, *J* = 7.3 Hz, 1H), 7.41 (d, *J* = 8.0 Hz, 1H), 7.30 (dd, *J* = 6.7, 1.3 Hz, 1H), 7.26–7.20 (m, 3H), 6.80 (d, *J* = 7.3 Hz, 1H), 6.56 (s, 1H), 6.19 (s, 1H), 2.17 (s, 3H), 1.47 (s, 9H), 0.57 (s, 6H). ¹³C NMR (CDCl₃): δ 151.0, 150.1, 147.2, 141.2, 140.2, 135.2, 134.8, 134.3, 130.5, 128.0, 127.9, 127.3, 127.2, 126.6, 123.3, 123.0, 120.8, 117.7, 115.5, 112.1, 35.0, 31.7, 22.3, 0.6.

3-(*Tert*-butyl)-5-(4-(*tert*-butyl)phenyl)-12,12-dimethyl-5,12-dihydrobenzo[*b*]naphtho[2,3-*e*][1,4]azasiline (5c)

This compound was prepared in a manner analogous to the synthesis of **1c** using **5b** (1.1 g, 1.95 mmol) to give **5c** as a white powder (yield: 0.75 g, 83%). ¹H NMR (CDCl₃): δ 8.06 (s, 1H), 7.75 (d, *J* = 8.0 Hz, 1H), 7.69–7.64 (m, 2H), 7.51 (d, *J* = 7.6 Hz, 1H), 7.45 (d, *J* = 8.1 Hz, 1H), 7.33–7.26 (m, 2H), 7.26–7.20 (m, 2H), 6.99 (dd, *J* = 7.6, 1.6 Hz, 1H), 6.70 (s, 1H), 6.31 (d, *J* = 1.5 Hz, 1H), 1.46 (s, 9H), 1.09 (s, 9H), 0.57 (s, 6H). ¹³C NMR (CDCl₃): δ 153.1, 151.0, 150.1, 147.1, 141.4, 135.3, 134.9, 134.0, 130.5, 127.9, 127.9, 127.3, 127.2, 126.5, 123.2, 122.9, 117.0, 115.6, 114.6, 111.9, 35.0, 34.9, 31.6, 31.0, 0.6.



1d, R¹ = R² = R³ = H

2d, R¹ = R² = H, R³ = *t*Bu

3d, R¹ = H, R² = R³ = *t*Bu

4d, R¹ = Me, R² = R³ = *t*Bu

5d, R¹ = R² = R³ = *t*Bu

12-(2,6-Di(prop-1-en-2-yl)phenyl)-5-phenyl-5,12-dihydrobenzo[*b*]naphtho[2,3-*e*][1,4]azaborinine (1d)

Boron tribromide (BBr₃, 0.53 g, 2.10 mmol) was added carefully to the flask containing **1c** (0.25 g, 0.70 mmol) at room temperature. After stirring at 60 °C for 3 h, the volatiles were removed under reduced pressure at the same temperature for 2 h. The crude mixture was dissolved in anhydrous toluene (10 mL), into which a toluene solution of (2,6-di(prop-1-en-2-yl)phenyl)lithium was added at 0 °C. The

latter solution was prepared by the addition of *n*-BuLi (2.5 M in hexane, 0.4 mL, 1 mmol) into a toluene solution of 2-bromo-1,3-di(prop-1-en-2-yl)benzene (0.20 g, 0.84 mmol) at 0 °C. After stirring at room temperature for 12 h, the mixture was quenched with saturated NH₄Cl solution and extracted with diethyl ether. The organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude product was subjected to silica gel column chromatography using CH₂Cl₂/hexane (1:6, v/v) to give **1d** as a yellow solid (yield: 0.10 g, 40%). ¹H NMR (CD₂Cl₂): δ 8.47 (s, 1H), 7.84 (d, *J* = 7.7 Hz, 2H), 7.78 (t, *J* = 7.3 Hz, 2H), 7.72–7.66 (m, 1H), 7.59 (d, *J* = 8.2 Hz, 1H), 7.45 (m, 7H), 7.31–7.25 (m, 1H), 7.08–7.00 (m, 2H), 6.70 (d, *J* = 8.7 Hz, 1H), 4.65 (s, 2H), 4.53 (s, 2H), 1.91 (s, 6H). ¹³C NMR (CD₂Cl₂): δ 148.2, 148.0, 147.8, 144.5, 142.5, 138.9, 137.6, 136.2, 133.2, 131.5, 129.2, 129.1, 127.9, 127.8, 127.4, 127.3, 125.9, 123.6, 119.4, 117.3, 116.7, 112.3, 112.3, 24.7. ¹¹B NMR (CD₂Cl₂): δ 55.3.

12-(4-(*Tert*-butyl)-2,6-di(prop-1-en-2-yl)phenyl)-5-phenyl-5,12-dihydrobenzo[*b*]naphtho[2,3-*e*][1,4]azaborinine (2d)

This compound was prepared in a manner analogous to the synthesis of **1d** using **1c**, BBr₃, and (4-(*tert*-butyl)-2,6-di(prop-1-en-2-yl)phenyl)lithium to give **2d** as a yellow powder (yield: 0.19 g, 40%). ¹H NMR (CD₂Cl₂): δ 8.50 (s, 1H), 7.85 (dd, *J* = 7.5, 1.9 Hz, 2H), 7.80–7.74 (m, 2H), 7.71–7.65 (m, 1H), 7.59 (d, *J* = 8.1 Hz, 1H), 7.45–7.37 (m, 6H), 7.28 (ddd, *J* = 8.0, 6.7, 1.2 Hz, 1H), 7.05–6.99 (m, 2H), 6.69 (d, *J* = 8.6 Hz, 1H), 4.64 (s, 2H), 4.52 (s, 2H), 1.93 (s, 6H), 1.48 (s, 9H). ¹³C NMR (CD₂Cl₂): δ 150.2, 148.7, 147.8, 147.7, 144.5, 142.5, 138.9, 137.6, 136.2, 133.1, 131.5, 131.1, 129.1, 129.1, 127.8, 127.8, 127.2, 123.6, 123.0, 119.3, 117.0, 116.7, 112.2, 35.0, 31.7, 24.8. ¹¹B NMR (CD₂Cl₂): δ 55.3.

12-(4-(*Tert*-butyl)-2,6-di(prop-1-en-2-yl)phenyl)-5-(4-(*tert*-butyl)phenyl)-5,12-dihydrobenzo[*b*]naphtho[2,3-*e*][1,4]azaborinine (3d)


This compound was prepared in a manner analogous to the synthesis of **1d** using **3c**, BBr₃, and (4-(*tert*-butyl)-2,6-di(prop-1-en-2-yl)phenyl)lithium to give **3d** as a yellow powder (yield: 0.29 g, 43%). ¹H NMR (CD₂Cl₂): δ 8.49 (s, 1H), 7.87–7.82 (m, 2H), 7.77 (d, *J* = 8.5 Hz, 2H), 7.60 (s, 1H), 7.44–7.37 (m, 4H), 7.33 (d, *J* = 8.4 Hz, 2H), 7.26 (d, *J* = 6.8 Hz, 1H), 7.07 (s, 1H), 7.01 (t, *J* = 6.8 Hz, 1H), 6.71 (d, *J* = 8.7 Hz, 1H), 4.64 (s, 2H), 4.52 (s, 2H), 1.92 (s, 6H), 1.51 (s, 9H), 1.48 (s, 9H). ¹³C NMR (CD₂Cl₂): δ 152.3, 150.1, 148.7, 148.0, 147.8, 144.7, 139.7, 138.9, 137.6, 136.2, 133.0, 130.3, 129.1, 128.4, 127.8, 127.2, 123.5, 123.0, 119.2, 117.0, 116.8, 112.2, 35.3, 35.0, 31.7, 24.8. ¹¹B NMR (CD₂Cl₂): δ 52.4.

12-(4-(*Tert*-butyl)-2,6-di(prop-1-en-2-yl)phenyl)-5-(4-(*tert*-butyl)phenyl)-3-methyl-5,12-dihydrobenzo[*b*]naphtho[2,3-*e*][1,4]azaborinine (4d)

This compound was prepared in a manner analogous to the synthesis of **1d** using **4c**, BBr₃, and (4-(*tert*-butyl)-2,6-di(prop-1-en-2-yl)phenyl)lithium to give **4d** as a yellow powder (yield: 0.37 g, 52%). ¹H NMR (CD₂Cl₂): δ 8.45 (s, 1H), 7.86–7.70 (m, 4H), 7.59 (d, *J* = 8.4 Hz, 1H), 7.43–7.35 (m, 3H), 7.29 (dd, *J* = 12.4, 8.3 Hz, 3H), 7.01 (s, 1H), 6.85 (d, *J* = 7.8 Hz, 1H), 6.52 (s, 1H), 4.63 (d, *J* = 1.5 Hz, 2H), 4.52 (s, 2H), 2.29 (s, 3H), 1.91 (s, 6H), 1.51 (s, 9H), 1.48 (s, 9H). ¹³C NMR (CD₂Cl₂): δ 152.2, 150.0, 148.7, 148.1, 147.7, 143.9, 139.6, 138.6, 137.6, 136.1, 130.3, 129.0, 128.3, 127.7, 127.6, 127.3, 123.4, 123.0, 120.9, 116.8, 116.7, 112.2, 35.3, 34.9, 31.7, 2.8, 22.6. ¹¹B NMR (CD₂Cl₂): δ 55.4.

3-(*Tert*-butyl)-12-(4-(*tert*-butyl)-2,6-di(prop-1-en-2-yl)phenyl)-5-(4-(*tert*-butyl)phenyl)-5,12-dihydrobenzo[*b*]naphtho[2,3-*e*][1,4]azaborinine (**5d**)

This compound was prepared in a manner analogous to the synthesis of **1d** using **5c**, BBr₃, and (4-(*tert*-butyl)-2,6-di(prop-1-en-2-yl)phenyl)lithium to give **5d** as a yellow powder (yield: 0.19 g, 40%). ¹H NMR (CD₂Cl₂): δ 8.45 (s, 1H), 7.86–7.70 (m, 4H), 7.59 (d, *J* = 8.4 Hz, 1H), 7.43–7.35 (m, 3H), 7.29 (dd, *J* = 12.4, 8.3 Hz, 3H), 7.01 (s, 1H), 6.85 (d, *J* = 7.8 Hz, 1H), 6.52 (s, 1H), 4.63 (d, *J* = 1.5 Hz, 2H), 4.52 (s, 2H), 2.29 (s, 3H), 1.91 (s, 6H), 1.51 (s, 9H), 1.48 (s, 9H). ¹³C NMR (CD₂Cl₂): δ 152.3, 150.0, 148.8, 148.0, 147.7, 144.7, 139.7, 138.7, 137.2, 136.1, 130.4, 129.1, 128.2, 127.7, 127.6, 127.5, 123.3, 123.0, 117.3, 116.8, 113.4, 112.1, 35.5, 35.3, 35.0, 31.7, 31.6, 31.2, 31.0, 24.8. ¹¹B NMR (CD₂Cl₂): δ 55.2.



BzNp (1), R¹ = R² = R³ = H

BuBzNp (2), R¹ = R² = H, R³ = ^tBu

Bu₂BzNp (3), R¹ = H, R² = R³ = ^tBu

Bu₂BzMeNp (4), R¹ = Me, R² = R³ = ^tBu

Bu₂BzBuNp (5), R¹ = R² = R³ = ^tBu

4,4,14,14-Tetramethyl-8-phenyl-8,14-dihydro-4H-8-aza-3a2-boraphenaleno[2,1,9,8-defg]tetracene (**BzNp, 1**)

The mixture of **1d** (0.10 g, 0.22 mmol) and scandium(III) triflate (Sc(OTf)₃, 0.22 g, 0.44 mmol) in anhydrous 1,2-dichloroethane (50 mL) was refluxed for 12 h. After cooling down, a saturated aqueous

solution of NaHCO₃ was added. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂. The combined organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude product was purified through silica gel chromatography using CH₂Cl₂/hexane (1:6, v/v) to give **1** as a yellow solid (yield: 0.04 g, 36%). ¹H NMR (CD₂Cl₂): δ 8.75 (m, 1H), 7.77 (m, 4H), 7.72–7.65 (m, 3H), 7.54 (t, *J* = 8.1 Hz, 1H), 7.47–7.39 (m, 5H), 6.97 (s, 1H), 6.48 (d, *J* = 8.4 Hz, 1H), 2.23 (s, 6H), 1.83 (s, 6H). ¹³C NMR (CD₂Cl₂): δ 160.3, 156.9, 154.8, 154.1, 147.5, 144.0, 142.5, 138.5, 133.8, 132.6, 131.5, 131.0, 130.1, 129.0, 128.5, 126.4, 124.8, 123.9, 122.5, 117.9, 112.6, 111.9, 44.8, 43.0, 35.0, 33.6. ¹¹B NMR (CD₂Cl₂): δ 43.1. HRMS (EI): *m/z* [M]⁺ calcd for C₃₄H₂₈BN: 461.2315; found: 461.2313.

2-(*Tert*-butyl)-4,4,14,14-tetramethyl-8-phenyl-8,14-dihydro-4H-8-aza-3a2-boraphenaleno[2,1,9,8-defg]tetracene (BuBzNp, 2)

This compound was prepared in a manner analogous to the synthesis of **1** using **2d** (0.19 g, 0.32 mmol) to give **2** as a yellow solid (yield: 0.07 g, 36%). ¹H NMR (CD₂Cl₂): δ 8.78–8.71 (m, 1H), 7.82–7.73 (m, 4H), 7.71–7.64 (m, 2H), 7.54 (t, *J* = 8.1 Hz, 1H), 7.48–7.38 (m, 5H), 6.95 (s, 1H), 6.46 (d, *J* = 8.1 Hz, 1H), 2.23 (s, 6H), 1.83 (s, 6H), 1.51 (s, 9H). ¹³C NMR (CD₂Cl₂): δ 160.0, 157.1, 155.7, 154.4, 154.3, 147.5, 144.0, 142.6, 138.5, 133.6, 131.5, 131.1, 130.1, 129.0, 128.5, 126.3, 125.4, 122.4, 121.9, 121.1, 117.9, 112.5, 111.8, 45.1, 43.2, 36.1, 35.1, 33.7, 31.8. ¹¹B NMR (CD₂Cl₂): δ 44.6. HRMS (EI): *m/z* [M]⁺ calcd for C₃₈H₃₆BN: 517.2941; found: 517.2936.

2-(*Tert*-butyl)-8-(4-(*tert*-butyl)phenyl)-4,4,14,14-tetramethyl-8,14-dihydro-4H-8-aza-3a2-boraphenaleno[2,1,9,8-defg]tetracene (Bu₂BzNp, 3)

This compound was prepared in a manner analogous to the synthesis of **1** using **3d** (0.29 g, 0.51 mmol) to give **3** as a yellow solid (yield: 0.14 g, 48%). ¹H NMR (CD₂Cl₂): δ 8.74 (m, 1H), 7.79 (dd, *J* = 5.5, 1.7 Hz, 2H), 7.75 (dd, *J* = 4.4, 1.7 Hz, 2H), 7.70 (dd, *J* = 6.4, 3.4 Hz, 1H), 7.54 (t, *J* = 8.1 Hz, 1H), 7.47–7.38 (m, 3H), 7.38–7.33 (m, 2H), 6.99 (s, 1H), 6.48 (d, *J* = 8.1 Hz, 1H), 2.23 (s, 6H), 1.83 (s, 6H), 1.51 (s, 9H), 1.50 (s, 9H). ¹³C NMR (CD₂Cl₂): δ 159.9, 157.1, 155.6, 154.3, 154.3, 152.1, 147.6, 144.1, 139.7, 138.5, 133.6, 130.2, 130.1, 128.5, 128.4, 126.2, 125.3, 122.4, 121.9, 121.1, 117.8, 112.6, 111.8, 45.0, 43.2, 36.1, 35.2, 35.1, 33.7, 31.8, 31.7. ¹¹B NMR (CD₂Cl₂): δ 41.2. HRMS (EI): *m/z* [M]⁺ calcd for C₄₂H₄₄BN: 573.3567; found: 573.3569.

2-(*Tert*-butyl)-8-(4-(*tert*-butyl)phenyl)-4,4,6,14,14-pentamethyl-8,14-dihydro-4H-8-aza-3a2-boraphenaleno[2,1,9,8-defg]tetracene (Bu₂BzMeNp, 4)

This compound was prepared in a manner analogous to the synthesis of **1** using **4d** (0.3 g, 0.51 mmol) to give **4** as a yellow solid (yield: 0.11 g, 32%). ¹H NMR (CD₂Cl₂): δ 8.73 (dd, *J* = 6.8, 3.5 Hz, 1H), 7.80–7.72 (m, 4H), 7.68 (dd, *J* = 6.5, 3.4 Hz, 1H), 7.44–7.39 (m, 2H), 7.36–7.31 (m, 2H), 7.24 (s, 1H), 6.93 (s, 1H), 6.33 (s, 1H), 2.39 (s, 3H), 2.22 (s, 6H), 1.82 (s, 6H), 1.51 (d, *J* = 2.9 Hz, 18H). ¹³C NMR (CD₂Cl₂): δ 159.9, 157.0, 155.6, 154.2, 152.1, 147.6, 144.3, 144.1, 139.6, 138.4, 133.5, 130.2, 130.0, 128.5, 128.4, 126.2, 125.2, 122.3, 121.8, 121.1, 117.7, 112.5, 111.7, 45.0, 43.1, 36.0, 35.2, 35.1, 33.6, 31.8, 31.6, 21.1. ¹¹B NMR (CD₂Cl₂): δ 44.7. HRMS (EI): *m/z* [M]⁺ calcd for C₄₃H₄₆BN: 587.3723; found: 587.3722.

2,6-Di-*tert*-butyl-8-(4-(*tert*-butyl)phenyl)-4,4,14,14-tetramethyl-8,14-dihydro-4H-8-aza-3a2-boraphenaleno[2,1,9,8-defg]tetracene (Bu₂BzBuNp, **5)**

This compound was prepared in a manner analogous to the synthesis of **1** using **5d** (0.2 g, 0.32 mmol) to give **5** as a yellow solid (yield: 0.06 g, 35%). ¹H NMR (CD₂Cl₂): δ 8.74 (dd, *J* = 6.5, 3.6 Hz, 1H), 7.76 (dd, *J* = 8.5, 5.7 Hz, 4H), 7.70 (dd, *J* = 6.3, 3.5 Hz, 1H), 7.46 (d, *J* = 1.0 Hz, 1H), 7.44–7.39 (m, 2H), 7.36 (d, *J* = 8.4 Hz, 2H), 7.02 (s, 1H), 6.48 (d, *J* = 1.0 Hz, 1H), 2.23 (s, 6H), 1.83 (s, 6H), 1.51 (d, *J* = 0.8 Hz, 18H), 1.25 (s, 9H). ¹³C NMR (CD₂Cl₂): δ 159.8, 157.2, 156.3, 155.4, 154.5, 154.1, 152.1, 147.7, 144.3, 139.7, 138.5, 130.3, 130.1, 128.5, 128.2, 126.1, 125.2, 122.3, 121.8, 121.2, 115.6, 111.7, 109.7, 45.1, 43.3, 36.0, 36.0, 35.2, 33.6, 31.8, 31.6, 31.3. ¹¹B NMR (CD₂Cl₂): δ 45.7. HRMS (EI): *m/z* [M]⁺ calcd for C₄₆H₅₂BN: 629.4193; found: 629.4193.

Cyclic voltammetry

Cyclic voltammetry measurements were carried out at room temperature in CH₂Cl₂ or THF (5 × 10⁻⁴ M) with a three-electrode cell configuration comprising platinum working and counter electrodes and an Ag/AgNO₃ (0.01 M in CH₃CN) reference electrode at room temperature. Tetra-*n*-butylammonium hexafluorophosphate (0.1 M) was used as the supporting electrolyte. The oxidation potentials were recorded at a scan rate of 100–200 mV/s and are reported against the ferrocene/ferrocenium (Fc/Fc⁺) redox couple. The HOMO and LUMO energy levels were determined from the electrochemical oxidation and reduction (*E*_{1/2}) peaks of cyclic voltammograms.

Computational details

The computational study was carried out using the PBE0 hybrid functional¹ and 6-31+G(d,p) basis set implemented in GAUSSIAN 16 software package.² The ground (S₀) and lowest singlet (S₁) excited states of compounds **1–5** were optimized using density functional theory (DFT) and time-dependent DFT (TD-DFT) calculations, respectively, with the same functional and basis set. Natural transition

orbitals (NTOs) were utilized to examine the characteristics for their electronic transitions from S_0 to S_1 state.³ The polarizable continuum model using the integral equation formalism (IEFPCM) was employed to take account for the influence of solvent medium (toluene) on molecular geometric and electronic structures.⁴ Nucleus-independent chemical shift (NICS) values were computed to identify the influence of increased conjugation length on the spectral wavelength at the PBE0/6-311++G(d,p)//PBE0/6-31G(d,p) level of theory.⁵ The NICS(1) values obtained at 1 Å above the ring centers were utilized to reduce the local effects of sigma bonds.⁶ The root-mean-square displacement values of structural deviation during transition between S_0 and S_1 states were computed using Multiwfn programs.⁷




Fig. S1. TGA curves of **1–5**.

Table S1. Oxidation and reduction potentials, optical bandgaps, and HOMO/LUMO energy levels of **1–5**.

compd	E_{ox} (V) ^a	E_{red} (V) ^a	E_g (eV)	HOMO (eV)	LUMO (eV)
1	0.52	−2.48	3.00	−5.32	−2.32
2	0.51	−2.49	3.00	−5.31	−2.31
3	0.48	−2.50	2.98	−5.28	−2.30
4	0.46	−2.59	3.05	−5.26	−2.21
5	0.44	−2.62	3.06	−5.24	−2.18

^aHalf-wave potential ($E_{1/2}$).




Fig. S2. UV/Vis absorption and PL spectra of 1–5 in toluene (2.0×10^{-5} M) at 298 K. The absorption and emission maximum wavelengths, Stokes shifts, and FWHMs are given.





Fig. S3. Transient PL decay curves of 1–5 in toluene at 298 K.



compd	λ_{PL} (nm)	PLQY (%)
1	481	~100
2	480	~100
3	480	~100
4	475	~100
5	478	~100

Fig. S4. PL spectra of PMMA films doped with 1 wt% **1–5** ($\lambda_{\text{exc}} = 335$ nm).

Table S2. The absorption wavelength (λ_{abs} in nm) and corresponding oscillator strength (f) for the lowest energy electronic excitation, i.e., S_0 to S_1 transition, of compounds **1–5** obtained using the TDDFT calculations at the PBE0/6-31+g(d,p) level of theory.

compd	λ_{abs}	f	Major contribution
1	430	0.1711	HOMO \rightarrow LUMO (98.3%)
2	427	0.1950	HOMO \rightarrow LUMO (98.2%)
3	429	0.2033	HOMO \rightarrow LUMO (98.2%)
4	425	0.2055	HOMO \rightarrow LUMO (98.1%)
5	429	0.1947	HOMO \rightarrow LUMO (98.2%)

Table S3. The emission wavelength (λ_{em} in nm) and corresponding oscillator strength (f) for the lowest energy electronic de-excitation, i.e., S_1 to S_0 transition, of compounds **1–5** obtained using the TDDFT calculations at the PBE0/6-31+g(d,p) level of theory.

compd	λ_{em}	f	Major contribution
1	456	0.1552	HOMO \rightarrow LUMO (98.5%)
2	452	0.1760	HOMO \rightarrow LUMO (98.4%)
3	454	0.1831	HOMO \rightarrow LUMO (98.5%)
4	452	0.1791	HOMO \rightarrow LUMO (98.4%)
5	454	0.1752	HOMO \rightarrow LUMO (98.5%)




Fig. S5. Natural transition orbitals (NTO) of compounds **1–5** for the transitions from S_0 to S_1 state obtained using the TDDFT calculations at the PBE0/6-31+g(d,p) level of theory.




Fig. S6. Structural overlap of the ground (S_0 , red) and lowest singlet excited (S_1 , blue) states for the compounds **1–5**. The root-mean-square displacement values of structural deviation (SD_{RMSD}) and corresponding reorganization energies (λ_{reorg}) are provided.




Fig. S7. ^{13}C (top) and ^1H (bottom) NMR spectra of **1a** in CDCl_3 (* from water and † from residual CHCl_3).




Fig. S8. ¹³C (top) and ¹H (bottom) NMR spectra of **4a** in CDCl₃ (* from water and † from residual CHCl₃).




Fig. S9. ¹³C (top) and ¹H (bottom) NMR spectra of **5a** in CDCl₃ (* from water and † from residual CHCl₃).




Fig. S10. ¹³C (top) and ¹H (bottom) NMR spectra of **1b** in CDCl₃.




Fig. S11. ^{13}C (top) and ^1H (bottom) NMR spectra of **3b** in CDCl_3 (* from water and † from residual CHCl_3).




Fig. S12. ¹³C (top) and ¹H (bottom) NMR spectra of **4b** in CDCl₃ (* from water and † from residual CHCl₃).




Fig. S13. ^{13}C (top) and ^1H (bottom) NMR spectra of **5b** in CDCl_3 (* from water).




Fig. S14. ^{13}C (top) and ^1H (bottom) NMR spectra of **1c** in CDCl_3 .




Fig. S15. ^{13}C (top) and ^1H (bottom) NMR spectra of **3c** in CDCl_3 .




Fig. S16. ^{13}C (top) and ^1H (bottom) NMR spectra of **4c** in CDCl_3 (* from water and † from residual CHCl_3).




Fig. S17. ^{13}C (top) and ^1H (bottom) NMR spectra of **5c** in CDCl_3 (* from water and † from residual CHCl_3).




Fig. S18. ¹H (bottom), ¹³C (middle), and ¹¹B (top) NMR spectra of **1d** in CD₂Cl₂ († from residual CHDCl₂).




Fig. S19. 1H (bottom), ^{13}C (middle), and ^{11}B (top) NMR spectra of **2d** in CD_2Cl_2 (* from water and † from residual CH_2Cl_2).




Fig. S20. ¹H (bottom), ¹³C (middle), and ¹¹B (top) NMR spectra of **3d** in CD₂Cl₂ († from residual CH₂Cl₂).




Fig. S21. ¹H (bottom), ¹³C (middle), and ¹¹B (top) NMR spectra of **4d** in CD₂Cl₂ († from residual CHDCl₂).




Fig. S22. ^1H (bottom), ^{13}C (middle), and ^{11}B (top) NMR spectra of **5d** in CD_2Cl_2 († from residual CHDCl_2).




Fig. S23. ¹H (bottom), ¹³C (middle), and ¹¹B (top) NMR spectra of **1** in CD₂Cl₂ (* from water and † from residual CHDCl₂).




Fig. S24. ^1H (bottom), ^{13}C (middle), and ^{11}B (top) NMR spectra of **2** in CD_2Cl_2 (\dagger from residual CHDCl_2).




Fig. S25. ^1H (bottom), ^{13}C (middle), and ^{11}B (top) NMR spectra of **3** in CD_2Cl_2 (* from water and † from residual CHDCl_2).




Fig. S26. ^1H (bottom), ^{13}C (middle), and ^{11}B (top) NMR spectra of **4** in CD_2Cl_2 (\dagger from residual CH_2Cl_2).




Fig. S27. ^1H (bottom), ^{13}C (middle), and ^{11}B (top) NMR spectra of **5** in CD_2Cl_2 († from residual CHDCl_2).

References

1. Adamo, C.; Barone, V. *J. Chem. Phys.* **1999**, *110*, 6158.
2. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Petersson, G. A.; Nakatsuji, H.; Li, X.; Caricato, M.; Marenich, A. V.; Bloino, J.; Janesko, B. G.; Gomperts, R.; Mennucci, B.; Hratchian, H. P.; Ortiz, J. V.; Izmaylov, A. F.; Sonnenberg, J. L.; Williams-Young, D.; Ding, F.; Lipparini, F.; Egidi, F.; Goings, J.; Peng, B.; Petrone, A.; Henderson, T.; Ranasinghe, D.; Zakrzewski, V. G.; Gao, J.; Rega, N.; Zheng, G.; Liang, W.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Throssell, K.; Montgomery Jr., J. A.; Peralta, J. E.; Ogliaro, F.; Bearpark, M. J.; Heyd, J. J.; Brothers, E. N.; Kudin, K. N.; Staroverov, V. N.; Keith, T. A.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A. P.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Millam, J. M.; Klene, M.; Adamo, C.; Cammi, R.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Farkas, O.; Foresman, J. B.; Fox, D. J. *Gaussian 16, Revision A.03*, Gaussian, Inc., Wallingford CT, 2016.
3. Martin, R. L. *J. Chem. Phys.* **2003**, *118*, 4775-4777.
4. Tomasi, J.; Mennucci, B.; Cammi, R. *Chem. Rev.* **2005**, *105*, 2999.
5. Chen, Z.; Wannere, C. S.; Corminboeuf, C.; Puchta, R.; Schleyer, P. v. R. *Chem. Rev.* **2005**, *105*, 3842-3888.
6. Schleyer, P. v. R.; Manoharan, M.; Wang, Z.-X.; Kiran, B.; Jiao, H.; Puchta, R.; Hommes, N. J. R. v. E. *Org. Lett.* **2001**, *3*, 2465-2468.
7. Lu, T.; Chen, F. *J. Comput. Chem.* **2012**, *33*, 580-592.